• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Reflexive Respiratory Panels Could Reduce Full-Panel Testing by 27 Percent

by
November 17, 2026
in Health
Reading Time: 6 mins read
0
Reflexive Respiratory Panels Could Reduce Full-Panel Testing by 27 Percent

Reflexive Respiratory Panels Could Reduce Full-Panel Testing by 27 Percent

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A retrospective evaluation conducted within a multi-hospital healthcare system demonstrates that implementing a customizable syndromic molecular panel with automatic reflex testing can maintain high diagnostic yields while reducing full-panel utilization by 27 percent. In an analysis of 300 sequential inpatient specimens collected across distinct seasonal periods of influenza-like illness, researchers at the Marshfield Clinic Research Institute and Marshfield Clinic evaluated the LIAISON PLEX Respiratory Flex Assay against the institutional standard-of-care BioFire Respiratory Panel 2.1. By tailoring reporting to a baseline configuration of seven high-impact pathogens and automatically reflexing negative samples to full-panel interrogation without requiring retesting, the clinical microbiology team demonstrated that diagnostic stewardship can curb unnecessary testing costs without compromising pathogen detection in symptomatic individuals presenting with acute upper respiratory tract infections.

Upper respiratory tract infections remain the most prevalent global etiology of acute illness, imposing substantial clinical morbidity, mortality, and economic hardship across both adult and pediatric patient populations. In the United States alone, the annual financial impact linked to these common conditions exceeds twelve billion dollars, compounded during seasonal surges by respiratory viruses that frequently present with clinically indistinguishable signs and symptoms. During the 2024 to 2025 respiratory illness season, influenza alone generated between 610,000 and 1.2 million hospitalizations alongside an estimated 27,000 to 130,000 deaths nationwide. Because clinicians cannot reliably differentiate causative organisms based solely on bedside clinical presentation, definitive molecular testing using nucleic acid amplification tests or rapid antigen assays is essential to guide appropriate antiviral therapy, prevent unnecessary antimicrobial administration, and inform infection prevention and control practices.

To navigate the expanding menu of molecular diagnostics, healthcare laboratories must constantly weigh clinical necessity, operational feasibility, and financial sustainability. Standard clinical laboratory practice frequently relies on maintaining separate platforms to accommodate varying levels of patient acuity and care settings. Low-risk outpatients seen in ambulatory clinics or urgent care settings are typically evaluated using four-target polymerase chain reaction panels restricted to SARS-CoV-2, Influenza A, Influenza B, and respiratory syncytial virus. Conversely, patients admitted to the intensive care unit with respiratory failure and multiple comorbidities may be tested on a syndromic panel covering the majority of possible respiratory infections. Verifying, maintaining, and quality-controlling multiple distinct platforms introduces substantial operational complexity, requiring duplicate validation protocols, divergent quality control schedules, and ongoing technologist competency assessments that place sustained demands on clinical microbiology resources.

The study cohort comprised 300 sequential patient specimens meeting institutional criteria for extended respiratory testing, such as intensive care unit admission, severe respiratory distress, or systemic immunocompromise, within the Marshfield Clinic Health System in northern and central Wisconsin. Testing was split evenly across two distinct seasonal epidemiologic windows designated by the Centers for Disease Control and Prevention surveillance metrics: a period of low influenza-like illness spanning April through June 2024 (n = 150) and a period of elevated influenza-like illness spanning January through March 2025 (n = 150). The mean patient age in the elevated cohort was 52.2 years, significantly younger than the 62.5-year mean documented during the low-activity cohort (p = 0.002), while patient sex distributions and underlying comorbid conditions—including active malignancy, diabetes mellitus, corticosteroid therapy, and solid organ transplantation—demonstrated no statistically significant differences between the two study periods.

Specimens underwent standard testing on the BioFire Respiratory Panel 2.1 followed by evaluation on the LIAISON PLEX Respiratory Flex Assay within 72 hours of collection while stored at 4 degrees Celsius. When initial evaluations revealed discrepant results between the two multiplex platforms, samples underwent additional testing performed by Diasorin using a validated two-step adjudication protocol. Nucleic acids underwent multiplex fragment analysis targeting between one and four analytes using fluorophore-labeled primers resolved by capillary electrophoresis on an Applied Biosystems 3730xl Genetic Analyzer. Amplicons meeting size and fluorescence thresholds advanced to confirmatory bidirectional sequencing, where sequences achieving PHRED quality scores of at least 20 across 90 percent of bases and minimum 100 contiguous base lengths were compared against reference sequences in the National Center for Biotechnology Information database using BLAST.

Initial concordance testing between the platforms yielded an unadjusted positive agreement of 84.8 percent and a negative agreement of 97.9 percent before discordant analysis. Five clinical specimens presented with a shared single positive target alongside a discordant secondary target and were excluded from comparative calculations because they met simultaneous criteria for concordance and discordance. Of sixteen specimens positive solely by the BioFire platform, confirmatory bidirectional sequencing verified the initial finding in only two instances, one specimen was omitted due to technical processing error, and twelve returned negative results. All four specimens initially identified as positive solely by the LIAISON platform tested negative upon referee sequencing. Following the removal of unconfirmed discordant samples, post-arbitration agreement resolved to 96.7 percent positive agreement across 92 validated positive samples and 100 percent negative agreement across 186 negative specimens.

Epidemiological surveillance across the two study intervals revealed pronounced seasonal variations in circulating respiratory pathogens identified by the flexible multiplex assay. During the low influenza-like illness interval, positive findings were dominated by Rhinovirus or Enterovirus at 14.7 percent (22 detections), followed by Human Metapneumovirus at 6.7 percent (10 detections), Parainfluenza Subtype 3 at 4.7 percent (7 detections), and isolated occurrences of RSV A/B and Parainfluenza Subtype 4 at 0.7 percent each, leaving 109 samples entirely negative. Conversely, testing throughout the elevated winter illness period revealed Influenza A as the most frequent pathogen at 11.3 percent (17 detections), accompanied by Seasonal Coronavirus at 6.7 percent, Enterovirus or Rhinovirus at 4.7 percent, Human Metapneumovirus and Mycoplasma pneumoniae at 4.0 percent each, RSV A/B at 3.3 percent, Adenovirus at 2.0 percent, SARS-CoV-2 at 1.3 percent, and Parainfluenza Subtype 4 at 0.7 percent.

Using empirical positivity observations, clinical actionability, and severity risk, the investigators retrospectively modeled a standardized seven-target base panel configured to maximize diagnostic yield while remaining within favorable procedural reimbursement coding thresholds. The proposed core inpatient panel encompassed SARS-CoV-2, Influenza A, Influenza B, and RSV—due to their established antiviral therapeutic indications and clinical propensity to cause life-threatening complications—supplemented by seasonal Coronavirus, Enterovirus/Rhinovirus, and Human Metapneumovirus as the most prevalent circulating pathogens. Retrospective modeling demonstrated that this baseline seven-target assembly would have successfully identified 33 of 41 positive specimens during low seasonal activity, achieving an 80.4 percent diagnostic yield, and 47 of 57 positive specimens during high seasonal activity, achieving an 82.5 percent diagnostic yield relative to standard full-panel testing.

A critical advantage of the customizable molecular architecture lies in software-directed reflexive reporting, which analyzes and releases masked diagnostic targets from the initial run without requiring instrument reloading, new reagent extraction, or technologist intervention. In the inpatient study cohort, coupling the seven-target base configuration to an automatic reflex protocol for negative specimens would have resolved 80 specimens on the initial tier alone, eliminating the necessity of unmasking complete panels in those patients and driving a 27 percent overall reduction in full syndromic panel utilization across the 300 evaluated cases. The authors noted that while a baseline reflex strategy could theoretically fail to capture dual infections where one pathogen resides on the base panel and a secondary coinfection resides on the masked panel, such diagnostic risks can be managed by reserving upfront comprehensive panels for critically ill ICU patients.

The study also examined the diagnostic consequences of extending the seven-target design to ambulatory settings, where clinical care currently relies on standard four-target assays. Comparing diagnostic yield against standard-of-care four-target outpatient testing demonstrated an increased chance of a diagnosis during both study periods. During the low-activity period, the seven-target configuration captured 80.5 percent of potential diagnoses compared to just 2.0 percent identified by four-target testing alone, driven largely by the high prevalence of non-targeted rhinoviruses and metapneumoviruses. During elevated winter activity, the seven-target panel yielded an 82.5 percent detection rate compared to 42.1 percent for the four-target assay. The authors emphasized that providing clinicians with a definitive viral diagnosis can actively support antibiotic stewardship initiatives by discouraging unnecessary antibacterial prescribing, provided integrated clinical decision pathways link laboratory results directly to clinical management teams.

Implementing flexible testing platforms also directly addresses recurring operational inefficiencies caused by duplicative testing orders within health systems. In this study, 45 percent of patients were tested with a four-target assay within 72 hours of being tested with a BioFire RP2.1 panel. Furthermore, custom and reflexive panels would have increased the laboratory's ability to respond to two scenarios that occurred during the study period: a Bordetella pertussis outbreak and a CDC request to increase influenza subtyping.

Despite these demonstrable laboratory benefits, the investigators underscored critical operational and epidemiologic considerations surrounding broad-scale adoption. Limiting diagnostic reporting to customized subsets could impair the automated transmission of pathogen surveillance data to public health registries, highlighting the need for software systems that aggregate de-identified diagnostic data in the background regardless of clinical billing tiers. Furthermore, because diagnostic performance in this investigation was derived from retrospective analysis of inpatient specimens, prospective clinical validation across diverse inpatient and outpatient cohorts remains necessary to measure direct impacts on patient outcomes, turnaround times, and total cost of care under dynamic procedural reimbursement schedules.

Subject of Research: Evaluation of customizable and reflexive syndromic molecular panels for respiratory pathogen detection and diagnostic stewardship

Article Title: Analysis of diagnostic yield and duplicative testing reduction using a customizable and reflexive syndromic panel

Article References: Pike, C., Higdon, E., Davy, K., Bulgrin, B., Arbefeville, S., & Wahlig, T. A. (2026). Analysis of diagnostic yield and duplicative testing reduction using a customizable and reflexive syndromic panel. Frontiers in Cellular and Infection Microbiology, 16, Article 1920142. https://doi.org/10.3389/fcimb.2026.1920142

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1920142

Keywords: respiratory tract infections, syndromic panels, diagnostic stewardship, molecular diagnostics, LIAISON PLEX, BioFire RP2.1, reflexive testing, influenza-like illness, pathogen prevalence, diagnostic yield, bidirectional sequencing, multiplex PCR, influenza A subtyping, Bordetella pertussis, antimicrobial stewardship, laboratory operations, clinical microbiology

News Source: Ophelia Keating. (November 17, 2026). Reflexive Respiratory Panels Could Reduce Full-Panel Testing by 27 Percent. Scienmag.

Tags: Antimicrobial Stewardshipbidirectional sequencingBioFire RP2.1Bordetella pertussisclinical microbiologydiagnostic stewardshipdiagnostic yieldinfluenza A subtypinginfluenza-like illnesslaboratory operationsLIAISON PLEXMolecular diagnosticsMultiplex PCRpathogen prevalencereflexive testingrespiratory tract infectionssyndromic panels
Share12Tweet7Share2ShareShareShare1

Related Posts

Dosiomics Machine Learning Model Predicts Late Urinary Toxicity After Prostate CyberKnife SBRT

Dosiomics Machine Learning Model Predicts Late Urinary Toxicity After Prostate CyberKnife SBRT

November 17, 2026
Wavefront Simulation Model Aligns Pediatric Astigmatism Prescriptions with Subjective Refraction

Wavefront Simulation Model Aligns Pediatric Astigmatism Prescriptions with Subjective Refraction

November 17, 2026

ADAR Enzymes Shape Cancer Progression Through Targeted RNA Editing, Review Finds

November 17, 2026

Review Finds Andes Virus Spreads Between People Especially After Close, Prolonged Exposure

November 17, 2026

POPULAR NEWS

  • Sesbania Hay Replacement Modifies Lamb Muscle Lipids and Meat Flavor Precursors

    Sesbania Hay Replacement Modifies Lamb Muscle Lipids and Meat Flavor Precursors

    29 shares
    Share 12 Tweet 7
  • Human Guided Knowledge Fusion Enhances Industrial Fault Diagnosis Graphs and Retrieval

    29 shares
    Share 12 Tweet 7
  • Geostatistical Kriging Maps Regional Ionospheric Storm Anomalies Across Türkiye

    29 shares
    Share 12 Tweet 7
  • Pediatric Mononucleosis Study Finds Exploratory Links Between Viral Load and Laboratory Measures

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dosiomics Machine Learning Model Predicts Late Urinary Toxicity After Prostate CyberKnife SBRT

Wavefront Simulation Model Aligns Pediatric Astigmatism Prescriptions with Subjective Refraction

Machine Learning Predicts Heat Transfer in Magnetized Hybrid Nanofluid Flow

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.